Evidence map›Paper›PMID 42397589›Full record

ReviewApplied microbiology and biotechnology2026

Perfusion development and its potential for cell therapy manufacturing with adherent cells.

Samuel Lukas Schneider, Vivian Ott, Regine Eibl

Abstract readReview
In one paragraph

Review in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Samuel Lukas SchneiderSchool of Life Sciences and Facility Management, Institute of Chemistry and Biotechnology, ZHAW Zurich University of Applied Sciences, 8820, Wädenswil, Switzerland. samuel.schneider@zhaw.ch.ORCID http://orcid.org/0000-0002-2756-408X
Vivian OttSchool of Life Sciences and Facility Management, Institute of Chemistry and Biotechnology, ZHAW Zurich University of Applied Sciences, 8820, Wädenswil, Switzerland.ORCID http://orcid.org/0000-0002-0208-3909
Regine EiblSchool of Life Sciences and Facility Management, Institute of Chemistry and Biotechnology, ZHAW Zurich University of Applied Sciences, 8820, Wädenswil, Switzerland.ORCID http://orcid.org/0000-0002-1840-8253

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Perfusion processing has established itself as a powerful intensification strategy for biopharmaceutical production processes of recombinant proteins. However, in the relatively young field of cell therapeutics manufacturing, this tool has been overlooked so far and with rising approvals, this field is in dire need of scalable and efficient production processes. In this regard, perfusion operation mode and related cell retention devices can be used to support upstream and downstream processing by automating operations, reducing contamination risk and ensuring stable cell quality. In this review, the history of cell retention technologies developed for suspension cell processing is laid out alongside the perfusion-based process intensification strategies they made possible. It is summarized how these technologies could be used to intensify the upstream processing of therapeutic adherent cells and to what degree perfusion processing of these demanding cells is already described in literature. Additionally, the applicability of cell retention devices for harvesting and downstream processing of therapeutic cells, which mainly consists of cell washing and formulation steps, is elaborated. In conclusion, through the implementation of scalable, single-use, good manufacturing practices compliant cultivation systems and cell retention devices, it should be possible substantially to accelerate the development of therapeutic adherent cell manufacturing strategies. KEY POINTS: • Perfusion can automate medium exchanges in therapeutic adherent cell manufacturing •  Perfusion technologies from suspension cell processing can be translated to adherent cell manufacturing • Scalable single-use perfusion systems are needed for the production of cell therapies.

Indexed as

Cell- and Tissue-Based TherapyCell Culture TechniquesPerfusionAnimalsBioreactorsCell AdhesionHumansCell retention deviceCell washingPerfusionProcess intensificationSingle-use technologiesStem cell

Identifiers

PMID42397589
PMCPMC13454009

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.